Infertility
Conditions
Interventions
Study Group:Participants will receive treatment for endometritis and adjustment of the endometrial microbiota simultaneously based on the results and recommendations of pathological and endometrial mi
Control Group:Participants will receive conventional treatment for endometritis based solely on pathological results in accordance with clinical routine. After medication, they will undergo frozen-tha
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Patients who have undergone 1–2 cycles of IVF/ICSI-ET and have not achieved clinical pregnancy. Those diagnosed with endometritis by hysteroscopic endometrial biopsy and with abnormal endometrial microbiota assessment; 2. Patients who have been informed and have signed the informed consent form for the RCT trial; 3. Patients with at least two good-quality embryos cryopreserved by vitrification; 4. Body mass index (BMI): 18.5 (inclusive)–30.0 kg/m^2 (inclusive); 5. Patients with normal ovarian reserve before the start of controlled ovarian stimulation (defined as: AFC >= 8; FSH < 8 mU/ml); 6. Patients with serum P level <= 1.5 ng/ml measured within 24 hours before hCG injection during the controlled ovarian stimulation cycle; 7. Patients with negative serological tests for HIV, HBV, HCV, and RPR.
Exclusion criteria
Exclusion criteria: 1. Patients with recurrent miscarriages (>2 biochemical pregnancies or >2 spontaneous abortions); 2. Patients with severe male factor infertility (sperm count 4cm, or hydrosalpinx, must have undergone surgery 3 months prior to endometrial sample collection. (Note: Patients whose pathological lesions have been treated before enrollment are still eligible to participate in the study.) 5. Patients who have undergone preimplantation genetic testing for aneuploidy (PGT-A) for embryo analysis; 6. Women who have received antibiotic treatment within one month prior to sample collection, excluding treatment for oocyte retrieval. Patients who require antibiotic treatment due to illness during the embryo transfer cycle; 7. Patients with any unstable or medical conditions that may affect patient safety and study compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical pregnancy rate;live birth rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| miscarriage rate;Ectopic Pregnancy Rate; | — |
Countries
China
Contacts
Public ContactYang Shuo
Peking University Third Hospital
Outcome results
None listed